Premium
Biomarker progressions explain higher variability in stage‐specific cognitive decline than baseline values in Alzheimer disease
Author(s) -
Dodge Hiroko H.,
Zhu Jian,
Harvey Danielle,
Saito Naomi,
Silbert Lisa C.,
Kaye Jeffrey A.,
Koeppe Robert A.,
Albin Roger L.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.04.513
Subject(s) - biomarker , medicine , oncology , cognitive decline , cognition , imaging biomarker , disease , neuroimaging , psychology , positron emission tomography , dementia , neuroscience , magnetic resonance imaging , radiology , biology , biochemistry
Background It is unknown which commonly used Alzheimer disease (AD) biomarker values—baseline or progression—best predict longitudinal cognitive decline. Methods 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and executive scores were the primary outcomes. Individual‐specific slope of the longitudinal trajectory of each biomarker was first estimated. These estimates and observed baseline biomarker values were used as predictors of cognitive declines. Variability in cognitive declines explained by baseline biomarker values was compared with variability explained by biomarker progression values. Results About 40% of variability in memory and executive function declines was explained by ventricular volume progression among mild cognitive impairment patients. A total of 84% of memory and 65% of executive function declines were explained by fluorodeoxyglucose positron emission tomography (FDG‐PET) score progression and ventricular volume progression, respectively, among AD patients. Conclusions For most biomarkers, biomarker progressions explained higher variability in cognitive decline than biomarker baseline values. This has important implications for clinical trials targeted to modify AD biomarkers.